Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Katherine Dunnington"'
Autor:
Wendy W. Yeh, Iain P. Fraser, Christine Fandozzi, Jennifer Talaty, Anna Mitselos, Marian Iwamoto, Xiaoyan Chu, Monika Martinho, Corinne Vandermeulen, Luzelena Caro, Xiaobi Huang, Zifang Guo, Jean Francois Denef, Katherine Dunnington, William D. Hanley, Deborah Panebianco, Jan de Hoon, Inge De Lepeleire, Joan R. Butterton, Hwa-Ping Feng, Lihong Du, Patricia Jumes, William L. Marshall, Robert Valesky
The combination of the hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor elbasvir and the NS3/4A protease inhibitor grazoprevir is a potent, once-daily therapy indicated for the treatment of chronic HCV infection in individuals coinfe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::437fd6dfa5132f3e6a6fda32702d0e3a
https://lirias.kuleuven.be/handle/123456789/635688
https://lirias.kuleuven.be/handle/123456789/635688
Autor:
Laura George, Bruce DeGroot, Dennis Swearingen, Xiaoli S. Glasgow, Daniel Tatosian, Eunkyung Kauh, Amy O. Johnson-Levonas, Katherine Dunnington, Nadia Cardillo Marricco, I.N. Gendrano
Publikováno v:
Clinical Pharmacology in Drug Development. 5:383-392
Omarigliptin is a dipeptidyl peptidase-4 inhibitor being developed as a once-weekly treatment for type 2 diabetes. This double-blind, double-dummy, randomized, 3-period balanced crossover study definitively evaluated the effects of a supratherapeutic
Autor:
Julie Grenier, Christine Brandquist, Nadia Cardillo-Marricco, Natacha Benrimoh, Mike Di Spirito, Katherine Dunnington
Publikováno v:
Pharmacokinetics and Adverse Effects of Drugs-Mechanisms and Risks Factors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::865ec28a0815866f0cd3062844959d8e
https://doi.org/10.5772/intechopen.74189
https://doi.org/10.5772/intechopen.74189